A total of 22 patients underwent baseline tumor biopsies and, of those, 13 had matched pre- and post-treatment biopsies assessable for change in CD8+ TILs and the change in CD8+/CD4+ ratio. The gene discussed is CD8A; the disease is neoplasm.